MRVI INVESTOR ALERT: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - The Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and inadequate internal controls over financial reporting [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Nelson v. Maravai LifeSciences Holdings, Inc., allows purchasers of Maravai securities from August 7, 2024, to February 24, 2025, to seek lead plaintiff status by May 5, 2025 [1][5]. - Allegations include that Maravai made false statements regarding its financial reporting, specifically concerning revenue recognition and the overstatement of goodwill [3][4]. - On February 25, 2025, Maravai announced a delay in its fiscal 2024 earnings release, citing the need for additional time to assess a potential non-cash impairment charge related to goodwill and an error in revenue recognition that affected approximately $3.9 million [4]. Group 2: Financial Impact - Following the announcement of the earnings release delay, Maravai's stock price dropped nearly 22$6.6 billion for investors in recent years [6].